Lexicon Pharmaceuticals Inc logo

LXRX

Lexicon Pharmaceuticals Inc

$3.03

Earnings Summary

Net Profits
$-24.59Mn

Highlights

Net Profits:

Lexicon Pharmaceuticals Inc’s net profit fell -36.09% since last year same period to $-24.59Mn in the Q2 2022. On a quarterly growth basis, Lexicon Pharmaceuticals Inc has generated -4.73% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Lexicon Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.14
EPS Estimate Current Year
-0.14

Highlights

EPS Estimate Current Quarter:

Lexicon Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.14 - a 12.5% jump from last quarter’s estimates.

EPS Estimate Current Year:

Lexicon Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.14.

Key Ratios

Key ratios of the Lexicon Pharmaceuticals Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.16
Return on Assets (ROA)
-0.42
Return on Equity (ROE)
-0.93
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Lexicon Pharmaceuticals Inc’s earning per share (EPS) fell -23.08% since last year same period to -0.16 in the Q2 2022. This indicates that the Lexicon Pharmaceuticals Inc has generated -23.08% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Lexicon Pharmaceuticals Inc’s return on assets (ROA) stands at -0.42.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Lexicon Pharmaceuticals Inc’s return on equity (ROE) stands at -0.93.

Dividend Per Share (DPS):

Lexicon Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-08-03
-0.16
-0.16
0%
2022-05-05
-0.16
-0.16
0%

Company Information

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications.

Organisation
Lexicon Pharmaceuticals Inc
Headquarters
2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381
Employees
78
Industry
Health Technology